These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 1539329

  • 1. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Bover J, Torras J, Alsina J.
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract] [Full Text] [Related]

  • 2. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM, Sánchez J, García J, Puig N, Sánchez P, Górriz JL, Cruz JM.
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract] [Full Text] [Related]

  • 3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 4. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF, Venkat KK, Kupin W, Dumler F, Gracida C, Uniewski M, Anaise D, Tang DH.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract] [Full Text] [Related]

  • 5. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N, Hong JH, DiBenedetto A, Clayton R, Miles AM, Markell MS, Distant DA, Fleishhacker J, Sommer BG.
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract] [Full Text] [Related]

  • 6. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ, Kimball JA, Barry JM.
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
    Howard RJ, Pfaff WW, Brunson ME, Ramos EL, Peterson JC, Croker BP, Scornik JC, Parris CJ, Fennell RS.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
    [No Abstract] [Full Text] [Related]

  • 9. Strategy for improving retransplantation in the CyA era.
    Dickerman R, Langley J, Brinker K, Trevino G, Melton L, Vergne-Marini P, Wilson PK.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract] [Full Text] [Related]

  • 10. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M, Gagnadoux MF, Guest G, Arsan A, Beurton D, Revillon Y, Niaudet P.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract] [Full Text] [Related]

  • 11. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C, Pulido F, Rodríguez-Paternina E, Algranati C, Bello I, Farias J, G-Millet V.
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract] [Full Text] [Related]

  • 12. Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group.
    Transplant Proc; 1994 Oct; 26(5):2522-4. PubMed ID: 7940775
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K, Munn SR, Sterioff S.
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO.
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract] [Full Text] [Related]

  • 17. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months.
    Banowsky LH, Wright FH, Kothmann R, Floyd M, Vick S.
    Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175
    [No Abstract] [Full Text] [Related]

  • 18. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA, Elbirk A, Rohr N, Jørgensen KA.
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract] [Full Text] [Related]

  • 19. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S, Kruse AP, Roby PV, Allen MD, Khan K, Fishbein D.
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract] [Full Text] [Related]

  • 20. Renal transplantation with cyclosporine in the elderly population.
    Velez RL, Brinker KR, Vergne-Marini PJ, Nesser DA, Long DL, Trevino G, Dickerman RM, Helfrich GB.
    Transplant Proc; 1991 Apr; 23(2):1749-52. PubMed ID: 1905073
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.